TEVA PHARMACEUTICAL

Teva’s UZEDY cuts schizophrenia readmissions & costs by ~26% while TEV‑749 shows promising efficacy for treatment‑resistant cases—see real‑world data.

Teva’s late‑September data releases confirm LAI dominance: low relapse rates, real‑world cost savings, and strong payer‑value positioning for olanzapine, risperidone, and AUSTEDO.

Teva’s share sale and new UZEDY data show modest liquidity risk but boost market positioning with real‑world evidence and clinician‑preferred LAIs.

Teva secures the first outpatient dexmedetomidine sublingual film for agitation in schizophrenia or bipolar disorder, aiming for a $500‑$600 million US market.

Teva Pharmaceutical’s 2025‑26 AGM confirms strong governance, steady revenue, cost‑control, and a focus on generics expansion & supply‑chain resilience, boosting shareholder confidence.

Teva and Medincell’s new joint venture on olanzapine LAI promises $30 M revenue and cost savings, but must overcome regulatory, competitive, and debt‑risk hurdles.

Teva teams up with Polpharma to launch a cost‑effective ocrelizumab biosimilar for MS, leveraging SC dosing and global sales to tap a $17.5 B market and secure early market share.

Teva’s new Ocrevus biosimilar license unlocks a $250‑$350 million MS market, blending low‑cost development, global reach and strategic growth in high‑barrier therapy.

Teva’s partnership with Medincell advances BEPO® long‑acting injectables, securing FDA/EMA approvals, expanding U.S., Canada and South Korean markets, and boosting psychiatric therapeutic reach.